Celcuity Inc.
CELCHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Celcuity Inc. focuses on Biotechnology services and products. Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. Valued at $3.19B, CELC is a mid-cap name in its sector. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC).
Market Cap
$3.19B
Beta
0.11
P/E (TTM)
—
P/E (Fwd)
-815.63
EPS (TTM)
$-4.31
EPS (Fwd)
$-0.08
ROE
-1433.7%
ROA
-25.8%
Cash
$754.0M
Total Debt
$754.4M
Free CF
-$72.0M
52W Change
-15.8%
Annual Financials
Cash vs Debt
Where CELC stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, CELC finished 43.04% below its 150-day moving average ($100.28) and 44.24% below its 200-day moving average ($102.43). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CELC overbought or oversold?
At the October 20, 2026 close, CELC's RSI(14) was 20.0, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $754.0M in cash, though total debt stands at $754.4M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company is burning cash, with free cash flow at -$72.0M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -1433.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
CELC's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing CELC's risk profile alongside its fundamentals and technical indicators provides a more complete picture.